Hikma Pharmaceuticals PLC - London-based drug maker with operations in Jordan - Notes that credit rating firm Fitch has upgraded Hikma’s long-term issuer default rating and senior unsecured rating to BBB from BBB- with a stable outlook. The rating affects Hikma Finance USA LLC’s $500 million in debt notes. ‘I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating,’ says Chief Financial Officer Khalid Nabilsi. S&P raised Hikma to BBB earlier this month. Hikma had $1.12 billion in net debt as of December 31, up from $976 million a year before. It had a net debt to core earnings ratio of 1.4 times.
Current stock price: 2,136.00 pence
12-month change: up 12%
Copyright 2025 Alliance News Ltd. All Rights Reserved.
